Repositorio Dspace

Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort

Mostrar el registro sencillo del ítem

dc.contributor.author Lozano-Rivas, Nuria
dc.contributor.author Rua-Figueroa, Íñigo
dc.contributor.author Freire-González, Mercedes
dc.contributor.author Turrion, Ana
dc.contributor.author Castellvi, Iván
dc.contributor.author Barbado-Ajo, Julia
dc.contributor.author Calvo-Alen, Jaime
dc.contributor.author Ortego-Centeno, Norberto
dc.contributor.author Díaz-Encarnacion, Monserrat
dc.contributor.author Pego-Reigosa, José-María
dc.contributor.author Ding, Bo
dc.contributor.author Galvez-Fernández, Marta
dc.contributor.author Bahamontes-Rosa, Noemi
dc.contributor.author Cervera, Ricard
dc.date.accessioned 2026-09-17T12:17:01Z
dc.date.available 2026-09-17T12:17:01Z
dc.date.issued 2026-07
dc.identifier.issn 2053-8790
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28169
dc.description.abstract OBJECTIVE: This analysis describes disease activity, organ damage and health-related quality of life (HRQoL) in patients with active SLE and moderate-to-severe disease activity from the Spanish SLE Prospective Observational Cohort Study (SPOCS) cohort. METHODS: SPOCS (NCT03189875) is a multicentre, prospective, observational cohort that followed-up adults with SLE every 6 months for up to 3 years. Disease activity was assessed using SLE Disease Activity Index 2000 (SLEDAI-2K) and Physician Global Assessment. Remission and Lupus Low Disease Activity State (LLDAS) definitions were therapeutic objectives; organ damage by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI); HRQoL by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Patient Health Questionnaire-8 (PHQ-8) and EuroQol 5-Dimension 5-Level (EQ-5D-5L). Patients were recruited from 18 Spanish sites (2017-2019). RESULTS: 99 patients were enrolled. At baseline, median (IQR) SLEDAI-2K was 8 (7-12); 45% of patients had organ damage (mean (SD) SDI 1.1 (1.6)). Remission was achieved by 13% at 6 months and at 24 months; sustained remission occurred in 9%. 24% achieved LLDAS at 6 months and ?22% thereafter; 8% maintained LLDAS for ?70% of follow-up. Median SLEDAI-2K declined to 4 at 6 months. New or worsening organ damage occurred in 11%, 8% and 12% of patients at 12, 24 and 36 months, respectively; mean SDI (SD) increased to 1.8 (2.0) by 36 months. Musculoskeletal, cutaneous, neuropsychiatric and renal systems were most frequently involved. HRQoL remained poor: 60%-75% had depressive symptoms (PHQ-8 ?5), 35%-50% moderate-to-severe depression (PHQ-8 ?10), mean FACIT-F ?30 (indicating persistent severe fatigue) and mean EQ-5D-5L index 0.70-0.75. Pain/discomfort affected up to 76% and anxiety/depression up to 66% of participants. CONCLUSIONS: In Spanish clinical practice, sustained remission and low disease activity state remain uncommon in moderate-to-severe SLE. Nearly half had organ damage at baseline, with continued accrual and impaired HRQoL. These findings highlight ongoing challenges in achieving lasting disease control and underscore the need for broader adoption of treat-to-target approaches to improve outcomes and prevent irreversible organ damage in this patient population. TRIAL REGISTRATION NUMBER: NCT03189875.
dc.language.iso eng
dc.publisher BMJ PUBLISHING GROUP
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Lupus Erythematosus, Systemic/drug therapy/psychology/physiopathology
dc.subject.mesh Quality of Life
dc.subject.mesh Spain
dc.subject.mesh Female
dc.subject.mesh Severity of Illness Index
dc.subject.mesh Prospective Studies
dc.subject.mesh Male
dc.subject.mesh Adult
dc.subject.mesh Middle Aged
dc.subject.mesh Treatment Outcome
dc.subject.mesh Fatigue
dc.subject.mesh Remission Induction
dc.title Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42463277
dc.relation.publisherversion https://lupus.bmj.com/lookup/doi/10.1136/lupus-2026-002054
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1136/lupus-2026-002054
dc.journal.title LUPUS SCIENCE & MEDICINE


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta